| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemangioma, Capillary | D018324 | 1 associated lipids |
| Dentin Dysplasia | D003805 | 1 associated lipids |
| Neoplasms, Squamous Cell | D018307 | 1 associated lipids |
| Fractures, Stress | D015775 | 2 associated lipids |
| Osteosclerosis | D010026 | 2 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Carcinoma, Neuroendocrine | D018278 | 2 associated lipids |
| Osteophyte | D054850 | 2 associated lipids |
| Prenatal Exposure Delayed Effects | D011297 | 2 associated lipids |
| Pericardial Effusion | D010490 | 2 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Waterman EA et al. | The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. | 2007 | Int. J. Cancer | pmid:17631639 |
| Sauer G et al. | [Pathophysiology of bone metastases in urologic carcinomas]. | 2007 | Urologe A | pmid:17632696 |
| Boyce BF and Xing L | Biology of RANK, RANKL, and osteoprotegerin. | 2007 | Arthritis Res. Ther. | pmid:17634140 |
| Zhu J et al. | EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. | 2007 | J. Biol. Chem. | pmid:17636266 |
| Toma CD et al. | Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. | 2007 | J. Pineal Res. | pmid:17645699 |
| Panzavolta S et al. | Setting properties and in vitro bioactivity of strontium-enriched gelatin-calcium phosphate bone cements. | 2008 | J Biomed Mater Res A | pmid:17647240 |
| Prigione A and Cortopassi G | Mitochondrial DNA deletions induce the adenosine monophosphate-activated protein kinase energy stress pathway and result in decreased secretion of some proteins. | 2007 | Aging Cell | pmid:17651460 |
| Tanaka S | Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system. | 2007 | Am. J. Nephrol. | pmid:17652963 |
| Rabin N et al. | A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. | 2007 | Leukemia | pmid:17657224 |
| Van Campenhout A et al. | Serum osteoprotegerin as a biomarker for vascular disease. | 2007 | Am. J. Cardiol. | pmid:17659953 |
| Miheller P et al. | Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. | 2007 | Inflamm. Bowel Dis. | pmid:17663430 |
| Son E et al. | Induction of alkaline phosphatase activity by L-ascorbic acid in human osteoblastic cells: a potential role for CK2 and Ikaros. | 2007 | Nutrition | pmid:17664058 |
| Geboes L et al. | Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis. | 2007 | Arthritis Rheum. | pmid:17665444 |
| González-Alvaro I et al. | Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. | 2007 | Ann. Rheum. Dis. | pmid:17666448 |
| Kim JG et al. | Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. | 2007 Sep-Oct | Menopause | pmid:17667143 |
| Castellino G et al. | Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. | 2007 | Lupus | pmid:17670845 |
| Lamoureux F et al. | Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. | 2007 | Cancer Res. | pmid:17671200 |
| Golledge J et al. | Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification. | 2008 | Atherosclerosis | pmid:17675038 |
| Mangiafico RA et al. | Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. | 2008 | Osteoporos Int | pmid:17676381 |
| Atteritano M et al. | Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. | 2007 | J. Clin. Endocrinol. Metab. | pmid:17682090 |
| Kmieć Z and Sokołowska I | [Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities]. | 2007 | Pol. Merkur. Lekarski | pmid:17684931 |
| Xiang GD et al. | [Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients]. | 2007 | Zhonghua Yi Xue Za Zhi | pmid:17686254 |
| Pérez-Castrillon JL et al. | Bone mineral density, bone remodeling and osteoprotegerin in patients with acute coronary syndrome. | 2008 | Int. J. Cardiol. | pmid:17689752 |
| Wendling D and Toussirot E | Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis? | 2007 | J. Rheumatol. | pmid:17696283 |
| Endres S et al. | Correlation of in vitro and in vivo results of vacuum plasma sprayed titanium implants with different surface topography. | 2008 | J Mater Sci Mater Med | pmid:17701309 |
| Vitovski S et al. | Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. | 2007 | J. Biol. Chem. | pmid:17702740 |
| Zhao HY et al. | Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. | 2008 | Osteoporos Int | pmid:17703270 |
| Dovio A et al. | Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis. | 2008 | Osteoporos Int | pmid:17703272 |
| Sarma PK et al. | Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. | 2008 | Clin. Rheumatol. | pmid:17703334 |
| de Lange J et al. | Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. | 2007 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:17703964 |
| Efstratiadis G et al. | Coronary calcification in patients with end-stage renal disease: a novel endocrine disorder? | 2007 Apr-Jun | Hormones (Athens) | pmid:17704043 |
| Gibellini D et al. | RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. | 2007 | J. Med. Virol. | pmid:17705184 |
| Mangan SH et al. | Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. | 2007 | Cardiovasc. Res. | pmid:17706953 |
| Wagner J et al. | Prevalence of OPG and IL-1 gene polymorphisms in chronic periodontitis. | 2007 | J. Clin. Periodontol. | pmid:17711477 |
| Avignon A et al. | Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. | 2007 | Diabetes Care | pmid:17712025 |
| Holecki M et al. | The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. | 2007 | Obesity (Silver Spring) | pmid:17712108 |
| Gengenbacher M et al. | Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. | 2008 | Ann. Rheum. Dis. | pmid:17720725 |
| Hacchou Y et al. | Inorganic polyphosphate: a possible stimulant of bone formation. | 2007 | J. Dent. Res. | pmid:17720862 |
| Shahbazi S et al. | Characterization of the interaction between von Willebrand factor and osteoprotegerin. | 2007 | J. Thromb. Haemost. | pmid:17723135 |
| Zhao Y et al. | Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway. | 2007 | J. Pharm. Pharmacol. | pmid:17725861 |
| Schlieper G et al. | [Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients?]. | 2007 | Dtsch. Med. Wochenschr. | pmid:17726653 |
| Tian QX et al. | [Effects of calcitonin on osteoblast cell proliferation and OPG/RANKL expression: experiment with mouse osteoblasts]. | 2007 | Zhonghua Yi Xue Za Zhi | pmid:17785093 |
| Angelopoulos NG et al. | Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. | 2007 Oct-Nov | Pediatr Hematol Oncol | pmid:17786784 |
| Yang J et al. | HMGB1 is a bone-active cytokine. | 2008 | J. Cell. Physiol. | pmid:17786958 |
| Nellemann B et al. | Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. | 2007 | Diabetes Care | pmid:17804683 |
| Garlet TP et al. | Cytokine expression pattern in compression and tension sides of the periodontal ligament during orthodontic tooth movement in humans. | 2007 | Eur. J. Oral Sci. | pmid:17850423 |
| Sennels HP et al. | Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17852826 |
| de la Piedra C et al. | Osteoinductive effect of bone bank allografts on human osteoblasts in culture. | 2008 | J. Orthop. Res. | pmid:17853479 |
| Heinonen SE et al. | Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. | 2007 | Circ. Res. | pmid:17872464 |
| Furuya T et al. | Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. | 2007 | Clin. Rheumatol. | pmid:17876645 |
| Zhang JH et al. | [Effects of the osteoclast in pathogenesis of multiple myeloma]. | 2007 | Zhonghua Xue Ye Xue Za Zhi | pmid:17877161 |
| Azuma Y | [Animal models of osteoporosis and development of anti-osteoporotic agents]. | 2007 | Nippon Yakurigaku Zasshi | pmid:17878615 |
| Strand M et al. | Polymorphisms at the osteoprotegerin and interleukin-6 genes in relation to first-ever stroke. | 2007 | Cerebrovasc. Dis. | pmid:17878722 |
| Dai Y et al. | [Effects of Migu Tablet on bone mineral density, serum levels of osteoprotegerin and its ligand and bone metabolic markers in patients with postmenopausal osteoporosis]. | 2007 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:17879531 |
| Prezelj J et al. | Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women. | 2008 Mar-Apr | Menopause | pmid:17882010 |
| Grzegorzewska AE and MÅ‚ot-Michalska M | Serum level of intact parathyroid hormone and other markers of bone metabolism in dialyzed patients. | 2007 | Adv Perit Dial | pmid:17886625 |
| Pulsatelli L et al. | Circulating RANKL/OPG in polymyalgia rheumatica. | 2007 Jul-Aug | Clin. Exp. Rheumatol. | pmid:17888221 |
| Kitchens JA et al. | Iontophoresis significantly increases the trans-dentinal delivery of osteoprotegerin, alendronate, and calcitonin. | 2007 | J Endod | pmid:17889691 |
| Oka H et al. | PGE2 activates cementoclastogenesis by cementoblasts via EP4. | 2007 | J. Dent. Res. | pmid:17890674 |
| Lossdörfer S et al. | Enamel matrix derivative promotes human periodontal ligament cell differentiation and osteoprotegerin production in vitro. | 2007 | J. Dent. Res. | pmid:17890675 |
| Hofbauer LC et al. | Estrogen therapy and coronary-artery calcification. | 2007 | N. Engl. J. Med. | pmid:17891834 |
| Kubota T et al. | NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. | 2007 | Arthritis Res. Ther. | pmid:17892600 |
| Vega D et al. | CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. | 2007 | J. Clin. Endocrinol. Metab. | pmid:17895323 |
| Tankó LB | Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe? | 2007 | Curr Opin Investig Drugs | pmid:17907059 |
| Shimizu S et al. | Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. | 2007 | Arthritis Rheum. | pmid:17907189 |
| Rodeo SA et al. | The effect of osteoclastic activity on tendon-to-bone healing: an experimental study in rabbits. | 2007 | J Bone Joint Surg Am | pmid:17908903 |
| Zheng Y et al. | Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. | 2007 | Cancer Res. | pmid:17909065 |
| Beke D et al. | [Clinical relevance of biomarkers in cancer related bone disease]. | 2007 | Wien Med Wochenschr | pmid:17922085 |
| Ugur-Altun B and Altun A | Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. | 2007 | Arch. Med. Res. | pmid:17923273 |
| Boyce BF and Xing L | The RANKL/RANK/OPG pathway. | 2007 | Curr Osteoporos Rep | pmid:17925190 |
| Kim JG et al. | Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. | 2008 Mar-Apr | Menopause | pmid:17925661 |
| Zhang X et al. | The effect of estrogen deficiency on receptor activator of nuclear factor kappa B ligand and osteoprotegerin synthesis in periapical lesions induced in rats. | 2007 | J Endod | pmid:17931931 |
| Maldonado S et al. | Mathematical modeling and analysis of force induced bone growth. | 2006 | Conf Proc IEEE Eng Med Biol Soc | pmid:17947010 |
| Allen CA et al. | Bilateral cavernous internal carotid aneurysms in a child with juvenile paget disease and osteoprotegerin deficiency. | 2008 | AJNR Am J Neuroradiol | pmid:17947367 |
| Keller ET et al. | New trends in the treatment of bone metastasis. | 2007 | J. Cell. Biochem. | pmid:17955492 |
| Galusca B et al. | Constitutional thinness: unusual human phenotype of low bone quality. | 2008 | J. Clin. Endocrinol. Metab. | pmid:17956951 |
| An JJ et al. | Expression and regulation of osteoprotegerin in adipose tissue. | 2007 | Yonsei Med. J. | pmid:17963332 |
| Roodman GD and Dougall WC | RANK ligand as a therapeutic target for bone metastases and multiple myeloma. | 2008 | Cancer Treat. Rev. | pmid:17964729 |
| Hikita A and Tanaka S | Ectodomain shedding of receptor activator of NF-kappaB ligand. | 2007 | Adv. Exp. Med. Biol. | pmid:17966383 |
| Sobańska I et al. | [The influence of sex and age on the osteoprotegerin level in the blood]. | 2007 | Wiad. Lek. | pmid:17966895 |
| D'Amelio P et al. | Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. | 2008 | J. Bone Miner. Res. | pmid:17967134 |
| Hirose S et al. | A histological assessment on the distribution of the osteocytic lacunar canalicular system using silver staining. | 2007 | J. Bone Miner. Metab. | pmid:17968489 |
| Shaarawy M et al. | Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. | 2007 | Clin. Chem. Lab. Med. | pmid:17970704 |
| Fujita K and Janz S | Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. | 2007 | Mol. Cancer | pmid:17971207 |
| Corallini F et al. | TRAIL and osteoprotegerin: a role in endothelial physiopathology? | 2008 | Front. Biosci. | pmid:17981533 |
| Brown SA et al. | Local effects of malignancy on bone. | 2007 | Curr Opin Endocrinol Diabetes Obes | pmid:17982348 |
| Xiang GD et al. | [Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients]. | 2007 | Zhonghua Yi Xue Za Zhi | pmid:17988532 |
| Geng L et al. | [Association between Val80 polymorphism of the CYP19 gene, A163G polymorphism of the OPG gene and bone mineral density in post-menopausal Chinese women]. | 2007 | Yi Chuan | pmid:17989043 |
| Nguyen KQ et al. | Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells. | 2007 | Endocrine | pmid:17992602 |
| Doumouchtsis KK et al. | sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. | 2007 | J. Endocrinol. Invest. | pmid:17993768 |
| Tat SK et al. | Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. | 2007 | Arthritis Res. Ther. | pmid:17996099 |
| You L et al. | Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. | 2008 | Bone | pmid:17997378 |
| Ohwada R et al. | The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. | 2007 | Endocr. J. | pmid:17998762 |
| Secchiero P et al. | Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. | 2008 | Blood | pmid:18000166 |
| Haaber J et al. | Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. | 2008 | Br. J. Haematol. | pmid:18005268 |
| Armstrong AP et al. | RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. | 2008 | Prostate | pmid:18008334 |
| Qin H and Yang FS | Calcitonin may be a useful therapeutic agent for osteoclastogenesis syndromes involving premature eruption of the tooth. | 2008 | Med. Hypotheses | pmid:18023993 |
| Stolina M et al. | Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. | 2007 | J. Immunol. | pmid:18025194 |
| Chakravarti A et al. | Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. | 2008 | Lab. Invest. | pmid:18040268 |
| Secchiero P and Zauli G | Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. | 2008 | Curr. Opin. Hematol. | pmid:18043245 |